Vanda Pharmaceuticals
VNDA
135 hedge funds and large institutions have $934M invested in Vanda Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 54 increasing their positions, 43 reducing their positions, and 12 closing their positions.
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
26% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 43
15% more capital invested
Capital invested by funds: $812M → $934M (+$122M)
3% more funds holding
Funds holding: 131 → 135 (+4)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.55% less ownership
Funds ownership: 94.63% → 94.08% (-0.55%)
5% less call options, than puts
Call options by funds: $683K | Put options by funds: $722K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$25.7M |
| 2 |
First Manhattan
New York
|
+$16M |
| 3 |
BlackRock
New York
|
+$11.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$4.83M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$4.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
-$15.1M |
| 2 |
Millennium Management
New York
|
-$10.1M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$6.43M |
| 4 |
AC
Armistice Capital
New York
|
-$6.29M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.22M |
VNDA Hedge Fund Activity: Q2 2018 in Review
135 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q2 2018, worth a combined $934M — up 15% from $812M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new VNDA positions and 12 closed out — a net gain of 4 holders — while 54 added to existing stakes and 43 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $25.7M. The largest seller was Rothschild & Co Asset Management US, cutting an estimated $15.1M.
- 135 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q2 2018, up from 131 in Q1 2018.
- Funds reported $934M of Vanda Pharmaceuticals stock for Q2 2018, up 15% quarter-over-quarter.
- 16 funds opened new Vanda Pharmaceuticals positions in Q2 2018 and 12 closed out, a net change of +4 holders.
- The largest Vanda Pharmaceuticals buyer in Q2 2018 was Consonance Capital Management, an estimated $25.7M added.
- The largest Vanda Pharmaceuticals seller in Q2 2018 was Rothschild & Co Asset Management US, an estimated $15.1M sold.
Based on aggregated 13F filings for Q2 2018.